239 related articles for article (PubMed ID: 25084203)
1. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
[TBL] [Abstract][Full Text] [Related]
3. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
4. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
Sims RP
J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
7. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy.
Nakagawa J; Takahata T; Chen Y; Saito K; Kamata K; Tachita T; Yamashita S; Saito K; Ueno K; Sato A; Sakuraba H; Niioka T
Cancer Chemother Pharmacol; 2023 Nov; 92(5):391-398. PubMed ID: 37610625
[TBL] [Abstract][Full Text] [Related]
9. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
10. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
[TBL] [Abstract][Full Text] [Related]
11. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
Skiles JL; Chiang C; Li CH; Martin S; Smith EL; Olbara G; Jones DR; Vik TA; Mostert S; Abbink F; Kaspers GJ; Li L; Njuguna F; Sajdyk TJ; Renbarger JL
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115708
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
[No Abstract] [Full Text] [Related]
14. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
15. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing.
Abaji R; Ceppi F; Patel S; Gagné V; Xu CJ; Spinella JF; Colombini A; Parasole R; Buldini B; Basso G; Conter V; Cazzaniga G; Leclerc JM; Laverdière C; Sinnett D; Krajinovic M
Pharmacogenomics; 2018 Oct; 19(15):1181-1193. PubMed ID: 30191766
[TBL] [Abstract][Full Text] [Related]
16. Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine.
Diouf B; Wing C; Panetta JC; Eddins D; Lin W; Yang W; Fan Y; Pei D; Cheng C; Delaney SM; Zhang W; Bonten EJ; Crews KR; Paugh SW; Li L; Freeman BB; Autry RJ; Beard JA; Ferguson DC; Janke LJ; Ness KK; Chen T; Zakharenko SS; Jeha S; Pui CH; Relling MV; Eileen Dolan M; Evans WE
Clin Transl Sci; 2021 Jul; 14(4):1490-1504. PubMed ID: 33742760
[TBL] [Abstract][Full Text] [Related]
17. Intracellular vincristine levels in lymphoblasts affect treatment outcome in childhood B-lymphoblastic leukaemia: Ma-Spore ALL 2010 study.
Jiang N; Wang L; Xiang X; Li Z; Chiew EKH; Koo YM; Lee HS; Lin HP; Tan AM; Quah TC; Kham SKY; Goh BC; Ariffin H; Yeoh AE
Br J Clin Pharmacol; 2021 Apr; 87(4):1990-1999. PubMed ID: 33037681
[TBL] [Abstract][Full Text] [Related]
18. Association of C3435T, C1236T and C4125A Polymorphisms of the MDR-1 Gene in Egyptian Children with Acute Lymphoblastic Leukaemia.
Talaat RM; Y K El-Kelliny M; El-Akhras BA; Bakry RM; Riad KF; Guirgis AA
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2535-2543. PubMed ID: 30256048
[TBL] [Abstract][Full Text] [Related]
19. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia.
ElFayoumi RI; Hagras MM; Abozenadaha A; Gari M; Abosoudah I; Shinawi T; Mirza T; Bawazir W
Pharmacol Rep; 2019 Feb; 71(1):90-95. PubMed ID: 30508724
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5 and NAT2 gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment outcome.
Silveira VS; Canalle R; Scrideli CA; Queiroz RG; Lopes LF; Tone LG
Mol Cell Biochem; 2012 May; 364(1-2):217-23. PubMed ID: 22215203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
